Physician profile
Colleen E Fairhurst
NPI 1093168114
$7,552.33
in general payments reported to CMS, 2019-2025
29 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,134 · 2022: $1,578 · 2023: $1,612 · 2024: $2,004 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,465 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.37 |
| Education | $374.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.58 | 2021-2025 | |
| Genzyme Corporation | $993.25 | 2021-2025 | |
| Leo Pharma INC. | $626.07 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $572.06 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $531.09 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $477.17 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $455.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $370.27 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $294.95 | 2021-2025 | Absorica Ld, Winlevi |
| Ucb, INC. | $293.86 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $261.95 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $236.81 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Sanofi-Aventis U.S. LLC | $189.94 | 2023-2024 | |
| Pfizer INC. | $152.59 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $109.00 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $93.53 | 2022 | |
| Incyte Corporation | $76.02 | 2021-2023 | Opzelura |
| Amgen INC. | $64.52 | 2024-2025 | Otezla, Otezla |
| Vyne Pharmaceuticals INC. | $62.54 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $61.76 | 2021-2023 | Duobrii, Arazlo, Jublia |
| Biofrontera INC. | $57.61 | 2021-2022 | |
| Organon LLC | $49.65 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $40.72 | 2024 | Ycanth |
| Epi Health, LLC | $40.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.74 | 2022-2023 | Cyltezo |
| Organogenesis INC. | $22.92 | 2021 | |
| Merck Sharp & Dohme LLC | $21.69 | 2023 | |
| Kyowa Kirin, INC. | $15.60 | 2023 | Poteligeo |
| Journey Medical Corporation | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Fairhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.